Slides on Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Review key data on when to use interleukin inhibitors in the course of psoriatic arthritis.
Vinod Chandran, MBBS, MD, DM, PhD
person default
Alexis Ogdie, MD, MSCE
Format: Microsoft PowerPoint (.ppt)
File Size: 338 KB
Released: December 29, 2020

Acknowledgements

Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novartis Pharmaceuticals Corporation

Related Content

Commentary by Dr. Vinod Chandran on using interleukin inhibitors secukinumab and guselkumab for axial manifestations of psoriatic arthritis, from CCO

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 11, 2021 Expired: January 10, 2022

Commentary from Dr Jim Treat on counseling parents and children about pros and cons of systemic therapy for pediatric plaque psoriasis, from CCO

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: January 8, 2021 Expired: January 7, 2022

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 29, 2020 Expired: December 28, 2021

Hear from expert Jim Treat, MD, on optimizing care of pediatric patients with plaque psoriasis, including systemic options, working with families, and more

person default Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 21, 2020 Expired: December 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue